Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Posted: April 21, 2025 at 2:44 am

WALTHAM, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced that on April 15, 2025 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors (the “Committee”) granted non-qualified stock options to two newly hired officers of the Company, each as an inducement material to each officer’s entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4).

Read the rest here:
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Related Posts